This grant allows us to coninue to participate in the study protocols of the Southwest Oncology Group, which involves investigational therapeutic approaches to patients with incurable malignancies, and investigational adjuvant studies in patients at high risk of recurrence. We believe in the philosophy of the pooling of patient data through cooperative inter-institutional efforts as a valid, efficient technique for quickly evaluating new therapy. We anticipate patient care and training programs in oncology to be improved in our own institution by application of multi-modality investigational approaches to the management of cancer. The faculty of our institution have a strong clinical research base especially in pharmacology, immunology, surgery, pathology, the development of new drug delivery systems, and phase I/II testting of new investigational anticancer agents. We therefore are able to provide leadership in many SWOG activities and major scientific input into the development and design of SWOG clinical trials. We also propose to expand and computerize our data management system and to coninue our high quality of patient accrual onto SWOG studies. We will make significant scientific contribution to the SWG effort to test the potential application of the Human Tumor Stem Cell Assay to the design of studies. As an established academic cancer treatment and research center, we will be able to provide the administrative, scientific and quality control link between concologists based in our community (Cancer Control Affiliates) and the Southwest Oncology Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA027057-07
Application #
3556853
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1980-01-01
Project End
1987-12-31
Budget Start
1986-01-01
Budget End
1986-12-31
Support Year
7
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Prebet, Thomas; Sun, Zhuoxin; Ketterling, Rhett P et al. (2016) Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol 172:384-91
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Whelan, Timothy J; Olivotto, Ivo A; Parulekar, Wendy R et al. (2015) Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med 373:307-16
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64

Showing the most recent 10 out of 194 publications